Teriflunomide (new indication: relapsing remitting multiple sclerosis (RRMS) in patients aged 10-17 years)

Subject:

• Active Substance: Teriflunomide
• Name: Aubagio^®
• Therapeutic area: Multiple sclerosis
• Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

Time table:

• Start: 01.08.2021
• Final decision by G-BA: 20.01.2022

Final decision:

• No additional benefit proved